NSE ScannerMedical Devices & Supplies · Medical Specialties · NSE: GKB · data 2026-10-31
Gkb Ophthalmics Limited
In plain words
Price: 23.3% below its 52-week high of ₹76.02.
Delivery: 73.6% of traded shares were kept for delivery over the last 10 sessions, against 81.8% over the last 50.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹150 cr |
| Net profit (last 12 months) | ₹3 cr |
| Sales growth, 3 years (yearly) | 25.5% |
| Profit growth, 3 years (yearly) | — |
At a glance
P/E 9.1, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 2.3%, ROCE 8.7%, operating margin 4.7%: how much profit it earns on the money it uses.
Debt/equity 0.22, Profit growth — and sales growth 25.5% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (2.3%).
- Thin operating margin (4.7%).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 60.7% over the last 20 sessions vs 61.6% in the 40 before (0.99x); shares delivered per day 0.99x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Gkb Ophthalmics Limited debt-free?
Its latest reported debt-to-equity ratio is 0.22.
What is Gkb Ophthalmics Limited's P/E ratio?
About 9.1, based on the last 12 months' earnings and a price of ₹58.3 (data 2026-10-31).
What is the 52-week high and low of Gkb Ophthalmics Limited?
The 52-week high is ₹76.02 and the 52-week low is ₹55.01.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Gkb Ophthalmics Limited | ₹58.3 | ₹30 cr | 9.1 | — | 2.3% | 8.7% | 0.22 | -30.6% |
| Yash Optics and Lens Limited | ₹118.05 | ₹292 cr | 32.3 | 2.9 | 9.5% | 11.6% | 0.05 | -9.2% |
| Nureca Ltd. | ₹293.8 | ₹285 cr | 61.1 | 1.5 | 1.1% | 3.4% | 0.01 | +13.0% |
| Avience Biomedicals Limited | ₹253.15 | ₹139 cr | 11.7 | 3.3 | 32.4% | 35.9% | 0.92 | -35.9% |
| Mohini Health & Hygiene Ltd. | ₹26.95 | ₹49 cr | — | 0.6 | -17.2% | -9.4% | 0.41 | -41.0% |
| Galaxy Medicare Limited | ₹18 | ₹27 cr | 6.9 | 0.7 | 10.6% | 11.9% | 0.1 | -16.3% |
Compare GKB with YASHOPTICS in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open GKB in NSE Scanner →